Specifically, we will evaluate liver fat content using magnetic resonance imaging (MRI) hepatic fibrosis using MR elastography and vibration-controlled transient elastography muscle composition and body fat distribution using water-fat separated whole body MRI and cardiac function, structure, and tissue characteristics, using cardiovascular MRI. We will prospectively recruit 400 patients with T2DM using biomarkers to assess their status. Therefore, the purpose of the current study is to evaluate the prevalence and severity of NAFLD in patients with T2DM by recruiting participants from primary care, using the latest imaging modalities, to collect a cohort of well phenotyped patients. Consequently, the prevalence and characteristics of T2DM patients with advanced fibrosis are unknown. However, its utility is inherently limited. Liver biopsy is the gold standard for assessing hepatic fibrosis. NAFLD patients with type 2 diabetes mellitus (T2DM) are at an increased risk of advanced fibrosis, which puts them at risk of cardiovascular complications, hepatocellular carcinoma, or liver failure. Non-alcoholic fatty liver disease (NAFLD) affects 20–30% of the general adult population.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |